REVIEW

Small molecules with antiviral activity against the Ebola virus

[version 1; peer review: 2 approved]

Nadia Litterman¹, Christopher Lipinski², Sean Ekins^{1,3}

¹Collaborative Drug Discovery, 1633 Bayshore Highway, Suite 342, Burlingame, CA, 94010, USA

²Christopher A. Lipinski, Ph.D., LLC., 10 Connshire Drive, Waterford, CT, 06385-4122, USA

³Collaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay Varina, NC, 27526, USA

v1 First published: 09 Feb 2015, 4:38
<https://doi.org/10.12688/f1000research.6120.1>
Latest published: 09 Feb 2015, 4:38
<https://doi.org/10.12688/f1000research.6120.1>

Abstract

The recent outbreak of the Ebola virus in West Africa has highlighted the clear shortage of broad-spectrum antiviral drugs for emerging viruses. There are numerous FDA approved drugs and other small molecules described in the literature that could be further evaluated for their potential as antiviral compounds. These molecules are in addition to the few new antivirals that have been tested in Ebola patients but were not originally developed against the Ebola virus, and may play an important role as we await an effective vaccine. The balance between using FDA approved drugs versus novel antivirals with minimal safety and no efficacy data in humans should be considered. We have evaluated 55 molecules from the perspective of an experienced medicinal chemist as well as using simple molecular properties and have highlighted 16 compounds that have desirable qualities as well as those that may be less desirable. In addition we propose that a collaborative database for sharing such published and novel information on small molecules is needed for the research community studying the Ebola virus.

Keywords

Ebola Virus , FDA approved drugs , Medicinal chemistry

Open Peer Review

Approval Status

	1	2
version 1
09 Feb 2015	view	view

1. **John A. Lowe III** , JL3Pharma LLC,
Stonington, USA

2. **Paul S Anderson**, Independent
Pharmaceuticals Professional, Lansdale, USA

Any reports and responses or comments on the article can be found at the end of the article.

This article is included in the **Emerging Diseases**
and **Outbreaks** gateway.

Corresponding author: Sean Ekins (ekinssean@yahoo.com)

Competing interests: N.K.L. works for Collaborative Drug Discovery Inc. S.E. works for Collaborations in Chemistry, and S.E. and C.A.L. consults for Collaborative Drug Discovery Inc.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2015 Litterman N *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Litterman N, Lipinski C and Ekins S. **Small molecules with antiviral activity against the Ebola virus [version 1; peer review: 2 approved]** F1000Research 2015, 4:38 <https://doi.org/10.12688/f1000research.6120.1>

First published: 09 Feb 2015, 4:38 <https://doi.org/10.12688/f1000research.6120.1>

Introduction

Viruses remain a constant threat to global health, with new infections from Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) killing more than 3 million people annually^{1,2}. The flavivirus that causes dengue fever infects up to 100 million people each year, leading to death in 2.5% of cases^{3,4}. Other viral outbreaks including severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory coronavirus (MERS-CoV), affect far fewer people but have high mortality rates and the potential to spread to epidemic size^{1,5,6}. Thus, even with the development of vaccines and other treatments, viruses lead to a large burden on human health.

More than 30 small molecule drugs have been developed that have activity against individual viruses, including HIV, influenza, HBV, and more recently HCV^{7,8}. However, a large number of virus types remain without any effective therapeutics, and there are few broad-spectrum anti-virals available. Thus, when viruses emerge that cause life-threatening infections, such as the recent Ebola virus epidemic in West Africa, there are no treatment options. Since it is likely that these and other types of infectious agents will emerge in the future, an important goal is to identify inhibitors to be available to contain such outbreaks.

A large array of drug discovery efforts have proven that despite their small size, viral genomes represent suitable targets for drugs. Direct-acting antivirals, which target viral proteins rather than the host's, have been the subject of extensive investigation³. Targets in this class fall into multiple categories: virus adsorption inhibitors, inhibitors of viral DNA or RNA synthesis, viral protease inhibitors required for virus maturation, and viral neuraminidase inhibitors required for virus elution⁷. In addition, cellular targets exist that are required for viral replication, including inosine monophosphate (IMP) dehydrogenase, which is required to supply the pool of guanosine triphosphate (GTP) that serves as a substrate for RNA and DNA, and S-adenosylhomocysteine (SAH) hydrolase, which is required for the methylation and hence maturation of viral DNA. While finding specific inhibitors to target each viral threat individually may be ideal, the cost-savings and feasibility of finding drugs that act as broad-spectrum antivirals, or those that target specific viral genus or family, is an important goal given the expense associated with developing any one drug for one disease³. There are important individual aspects of each virus, and viral family to consider, but nonetheless, many mechanisms of the viral life cycle are mirrored across families, and thus represent opportunities to learn from the many experimental studies that have already been performed.

Like many around the world, we have been watching the devastating effects of the Ebola virus in West Africa. We have been impressed by the important contributions of the health organizations and the personal sacrifices the medical workers are making to serve patients and hamper the spread of disease. And yet we began to wonder, why has there been relatively little focus on small molecules apart from a recent review of Ebola virus therapeutic strategies in general⁹? Small molecules have several advantages over other therapeutic approaches including the ability to be produced at a large scale and stability necessary for broad distribution.

We felt it was time to therefore focus more on small molecules while we await a vaccine. We have found that indeed there is much prior knowledge regarding small molecules that have been shown to be active against the Ebola virus *in vitro* or in animal models^{10–13}, including a number of FDA-approved drugs^{14–16}. A thorough literature search of PubMed, and CAS SciFinder™ (CAS, Columbus OH) using terms including “Ebola” identified 55 molecules suggested to have activity against Ebola virus *in vitro* and/or *in vivo* (Supplemental Table 1).

FDA approved small molecules with activity against the Ebola virus

Recently, a pharmacophore¹⁷ was generated from four FDA approved compounds for other diseases (non-antivirals) resulting from two high throughput screens against the Ebola virus^{14,15} and closely matched the receptor-ligand pharmacophores for the Ebola Viral protein 35 (VP35)¹⁰. Follow-up docking studies suggested that these compounds may have favorable inhibitory interactions with this receptor. VP35 is a cofactor in the RNA polymerase transcription complex, and helps the virus evade the immune response by blocking activation of the interferon regulatory factor 3, which is required for the induction of interferons alpha and beta. Thus, blocking VP35 should allow for an enhancement of the host immune response to the Ebola virus. It is proposed that similar compounds may be acting via a closely related mechanism, though there has been no experimental evidence to directly prove this yet.

Another recent study¹⁶ has highlighted the ability of three clinically approved ion channel blockers to inhibit the Ebola virus cellular entry. The drugs amiodarone, dronedarone, and verapamil, were given at concentrations that are possible in human serum, and were effective against a number of filoviruses. The authors hypothesized that these drugs may act by disrupting late endosomal processing or by disrupting calcium signaling that is required for viral entry.

Of course, none of these aforementioned FDA approved drugs were designed to target the Ebola virus. Amodiaquine and chloroquine are antimalarials, clomiphene and toremifene are selective estrogen receptor modulators. Amiodarone, dronedarone, and verapamil are anti-arrhythmics. Interestingly, all of these compounds have a common tertiary amine feature, which may suggest they could act through similar mechanism^{18,19}. However, they are all orally bio-available and generally safe for humans. Thus these repurposed drugs may represent a fast track to potential evaluation and approval as a feasible option for preventing the spread and mortality associated with the Ebola virus in a large population.

Small molecules tested in humans with the Ebola virus

Several small molecules have actually been tested in very small numbers of humans for activity against the Ebola virus. For example there has been some press on favipiravir, which is undergoing phase 3 clinical trials in the US for influenza and is approved in Japan, as it has shown promising efficacy against the Ebola virus in mice²⁰. Favipiravir is thought to act by inhibiting the viral RNA-dependent RNA polymerase selectively and has demonstrated activity against a number of other viruses. At least one Ebola patient, who has since recovered, was given favipiravir²¹, and Japan offered to supply it to the World Health Organization.

A second experimental drug, brincidofovir²², in phase 3 clinical trials for treatment of cytomegalovirus and other DNA viruses has shown efficacy against the Ebola virus *in vitro* and animal studies are ongoing²³. Brincidofovir is thought to mimic cytidine, a building block of DNA, and thereby inhibit viral DNA polymerases, and its mechanism of action against the Ebola virus, an RNA virus, is yet unknown. Brincidofovir, which has demonstrated safety in humans, has been given to at least two Ebola virus patients, one in Dallas and one in Nebraska. While unfortunately the Dallas patient died, the Nebraska patient survived²⁴. It is of course too early to know the effect of this molecule on the progression of the disease. This compound is a pro-drug that is converted into the active antiviral, cidofovir diphosphate. Brincidofovir has higher oral bioavailability, intracellular concentrations of drug and increased antiviral potency²². This compound only appeared in the literature in 2014 and there is very little published information.

Beyond these early stage drugs, there are a number of other compounds that have been identified as active against the Ebola virus as summarized by Erik De Clercq⁹. While many are not ready for in human use, they may present an attractive starting point to be refined in a future drug discovery effort. For example, a novel nucleoside analog, BCX4430 demonstrated efficacy in mice and non-human primates against the Ebola virus²⁵. This compound targets viral RNA polymerase activity by inducing early termination of transcription and thus blocking replication. BCX4430 is not only active against Ebola virus, but also targets other members of the Filovirus family as well as 8 other RNA virus families. Because of the potent and efficacious effects, BCX4430 is being fast-tracked for clinical trials in humans.

Medicinal chemistry analysis of small molecules active against the Ebola virus

We have recently described an expert's medicinal chemistry²⁶ analysis of the over 320 NIH probe compounds using public and commercial sources of chemical structures and the issues related to doing this type of analysis²⁷. The likely chemistry quality of these probes was scored based on a number of criteria including literature related to the probe and potential chemical reactivity. Through a series of machine learning models, we also computationally predicted the scores which were being identified through a painstaking manual process²⁶. External validation and comparison with other

measures of drug-likeness and filtering rules suggested a comparable level of accuracy²⁶.

We have now carefully analyzed in a similar manner the 55 small molecules with activity against the Ebola virus identified from our literature search. The chemist's (C.A.L.) decisions on compound quality are summarized in [Supplemental Table 1](#). In contrast to the previous work in scoring compounds as chemical probes, the current aim is very specific - to treat a very serious viral disease for which there is a phenotypic readout. All the known drugs in clinical use were rejected as the chemist looked for compounds that looked more interesting in his opinion. Only 16 out of 55 were selected as desirable in this analysis with no potential problems based on medicinal chemistry experience. In addition to this manual approach, we applied computational filters such as Pan Assay INterference compoundS (PAINS) to identify potentially problematic compounds from structures^{28,29} ([Supplemental Table 1](#)). PAINS analysis was enabled using the MMDS mobile app³⁰. Based on this approach we have identified several molecules that appear problematic and agreed with the medicinal chemistry analysis. For example 4 molecules appear to fail the PAINS filters, including the rhodanine compound LJ-001 which was found to be active against numerous enveloped viruses and was found through a screen of inhibitors of Nipah virus entry (IC₅₀ 1μM)³¹. *In vivo* a steady state plasma concentration could not be maintained at a therapeutic level. Rhodanines are known to be problematic PAINS compounds^{28,29}. Interestingly amodiaquine was not scored favorably by PAINS or the medicinal chemist, yet this is a successful antimalarial drug.

In addition we analyzed the simple chemical properties (calculated in the Collaborative Drug Discovery (CDD) Vault (Collaborative Drug Discovery, Inc) using the Chemaxon toolkit (Chemaxon, Budapest, Hungary)) of the molecules and compared these to their medicinal chemistry classification ([Table 1](#)). The mean calculated molecular property values for compounds were compared using the *t*-test and ANOVA with JMP v. 8.0.1 (SAS Institute, Cary, NC). Significant differences were noted in LogP and Lipinski Rule of 5 violations between desirable and undesirable compounds although one molecule SARA-133 skewed the data with a molecular weight over 3000 ([Table 1](#)). Removal of this compound leads to significant differences for molecular weight, number of hydrogen bond

Table 1. Mean ± SD molecular properties calculated in CDD Vault using ChemAxon software for the 55 molecules with activity against the Ebola virus. * statistically significant $p < 0.05$ using the *t*-test and ANOVA. ** statistically significant $p < 0.0001$ using the *t*-test and ANOVA. Note data are skewed by SARA-133. When this molecule is removed the mean values and significance data are shown in parentheses.

	Molecular weight	LogP	H-bond donors	H-bond acceptors	Lipinski Rule of 5 violations	pKa	Heavy atom count	Polar Surface Area	Rotatable bond number
Undesirable (n = 39)	508.49 ± 447.43 (438.66 ± 101.47)	3.75 ± 4.15 (4.35 ± 1.79)	2.38 ± 5.04 (1.60 ± 1.35)	6.33 ± 10.49 (4.68 ± 2.04)	0.69 ± 0.73 (0.63 ± 0.63)	7.45 ± 4.22 (7.34 ± 0.64)	35.79 ± 30.78 (31.00 ± 7.24)	104.03 ± 197.71 (72.78 ± 32.23)	9.67 ± 14.07 (7.47 ± 3.29)
Desirable (N = 16)	371.38 ± 107.47 (*)	1.22 ± 2.55* (**)	3.19 ± 1.94 (*)	5.25 ± 1.77	0.31 ± 0.48* (*)	8.27 ± 3.33	26.06 ± 7.47 (*)	103.36 ± 32.81 (*)	6.37 ± 6.04

donors, heavy atom count and polar surface area, in addition to logP and Lipinski Rule of 5 violations for desirable compounds versus undesirable compounds.

Collaboration for the Ebola virus drug discovery

The research described for small molecule inhibitors against the Ebola virus has occurred in a disconnected manner and there have been few efforts to summarize the total medicinal chemistry efforts to date. We think this research can learn from other areas in which there are currently efforts to improve collaboration and screening. In the area of Tuberculosis research, funding from the Bill and Melinda Gates Foundation and The European Commission have enabled the TB Drug Accelerator and the More Medicines For Tuberculosis, as large-scale collaborations between academia, research institutes and industry. These collaborations have promoted the selective sharing of related data in a secure environment between collaborators using the CDD Vault³² (Figure 1). The centralized availability of publicly available data on compounds screened for activity against *Mycobacterium tuberculosis* enables researchers to leverage the existing literature alongside their private data. This knowledge can be used for building of validated computational models that can help in selecting additional compounds or lead optimization^{33,34}, saving time and effort. By organizing the data on small molecules tested against the Ebola virus similarly in a central database and using machine learning models based on public data may help identify additional compounds for testing. Such an effort may also prevent duplication of efforts as we have seen with the screening of multiple libraries of FDA approved compounds against the Ebola Virus¹⁴⁻¹⁶. In order to catalyze this

we have made the 55 compounds (Supplemental Table 1) freely available as a dataset in CDD Public (<https://app.collaborativedrug.com/register>). The compound representation in CDD Vault can be accessed via the text compound descriptors (as in the Supplemental Table 1) or in a batch connection table format as an MDL format structure data file (*.sdf) that is universally read by all chemistry aware software. Being able to easily retrieve the chemical structures in machine retrievable form has considerable value. Identifying compounds by name or company code number does not per se allow direct access to chemical structure and often fails entirely to link compound identifier with the chemistry structure of the compound. InChIKey has the great advantage of being searchable on the web (e.g. via Google) but requires a lookup table (e.g. EMBL's Unichem) to get back to the chemical structure. SMILES and InChi representations allow direct access to chemical structure and are compatible with structure searching in most public chemistry databases as well as the proprietary chemistry ACS CAS SciFinder database. The IUPAC name is universally used in naming chemical compounds in patents and software exists for going from IUPAC name to chemical structure.

Conclusions

The compounds which are FDA approved drugs for other diseases¹⁴⁻¹⁶ but with activity against Ebola virus *in vitro* or *in vivo* may represent useful starting points with the advantage that much is known regarding their ADME and Tox properties. However they may not be ideal in the opinion of a medicinal chemist. By bringing together all 55 compounds described in the literature with activity against the Ebola virus, this body of evidence

55 Selected:

Select	Molecule	Molecule Fields	Information on Ebola Compounds				ebola scoring data					
all	none	Synonyms	Alternative Name	Publication Link	PMID	Description	Medicinal C. Evaluation	Medicinal C. nt Comments	Stereo Count (MMDS)	Stereo undefined (MMDS)	Stereo Confidence	PKIN3 Filters (MMDS)
	<div><div>summarydetailsflag outlines</div><div> </div><div>NS-0110428 Nadia's Sandbox</div></div>	317302 AID502_104908	Brincidofovir	http://www.ncbi.nlm.nih.gov/pubmed/25120093	25120093E+06	An experimental antiviral drug, brincidofovir, in phase 3 clinical trials for treatment of cytomegalovirus and other DNA viruses, has shown efficacy against the Ebola virus in vitro and in animals. Brincidofovir is thought to mimic cytosine, a building block of DNA, and thereby inhibit viral DNA polymerase. It is not yet clear what is the mechanism of action by which it inhibits the Ebola virus, which as an RNA virus does not contain DNA or a DNA polymerase. Brincidofovir, which has demonstrated safety in humans, has been given to three Ebola virus patients in the U.S. of which two survived. It is of course too early to know the effect of this molecule on the progression of the disease. This compound is a pro-drug that is converted into the active antiviral, disodium phosphinate. Brincidofovir has higher oral bioavailability, intracellular concentrations of drug and increased antiviral potency.	1	antiviral produg	2	1	0.5	n/a
	<div><div>summarydetailsflag outlines</div><div> </div><div>NS-0204118 Nadia's Sandbox</div></div>	C795-0925	C795-0925	http://www.ncbi.nlm.nih.gov/pubmed/25144302	25144302E+06	C795-0925 and F894-1532, identified through a high content image based screen against Rift Valley fever virus, inhibit virus replication and are effective against EBOV in cells.	1	chiral, stable center	4	4	0.0625	n/a
	<div><div>summarydetailsflag outlines</div><div> </div><div>NS-0124914 Nadia's Sandbox</div></div>	220677 AID502_121000 Favipiravir	Favipiravir	http://www.ncbi.nlm.nih.gov/pubmed/24583123	24583123E+06	Several small molecules have actually been tested in small numbers of humans for Ebola activity. Favipiravir (also known as Avigan), which is undergoing phase 3 clinical trials in the US for influenza and is approved in Japan, has shown promising efficacy against Ebola virus in mice. Favipiravir is thought to act by inhibiting the viral RNA-dependent RNA polymerase selectively and has demonstrated activity against a number of viruses. At least three Ebola patients, who have since recovered, were given favipiravir, and Japan has offered to supply it to the World Health Organization.	1	fine, looks like small drug, transporter substrate	0	0	1	n/a
	<div><div>summarydetailsflag outlines</div><div> </div><div>CDD-862137</div></div>	compound 7910528	compound 7910528	http://www.ncbi.nlm.nih.gov/pubmed/24501399	24501399E+06	Through a HTS assay designed to identify compounds that inhibit cathepsin L, cleavage of viral glycoproteins from SARS-CoV, EBOV, Hendra, and Nipah viruses, these small molecules were found to be effective in pseudovirus inhibition assay.	1	fine if simple	0	0	1	n/a

Figure 1. An example of small molecules active against Ebola virus data in the CDD Vault. This illustrates how a comprehensive database could be created and used for collaborations. 55 molecules with predicted properties and scores from an experienced medicinal chemist and filters and shown alongside the publication link and target information.

may be more convincing than each study in isolation. In addition it allows us to consider structural features and molecular properties, which may provide insights into the target or mechanism of action. It is unclear whether any of the 55 compounds might also have activity when used as combination therapy as is the current standard of care for HIV, in order to overcome drug resistance, and this needs experimental evaluation. Clearly, we are a considerable distance from having an FDA approved drug for the Ebola virus, but this analysis illustrates that there are already drugs on the shelf that can be potentially repurposed in a shorter time period and at a lower cost and yet they do not appear to have been tested in patients with the Ebola virus. In addition there are at least 16 molecules which in the opinion of an experienced medicinal chemist are possibilities for further optimization. While novel compounds are likely more commercially viable they also will require considerable effort to assess safety. Resources will need to be allocated to this effort and administrators and scientists should perhaps consider some of the medicinal chemistry insights we have provided as well as using a collaborative database to share molecules that are active amongst all scientists. It is hoped these efforts could inspire further drug discovery efforts around small molecules.

To illustrate the level of interest in repurposing efforts for the Ebola virus, the following studies were identified upon submission that describe additional compounds as well as those already described herein^{35–37}.

Author contributions

All authors contributed to the collaborative writing of this project.

Competing interests

N.K.L. works for Collaborative Drug Discovery Inc. S.E. works for Collaborations in Chemistry, and S.E. and C.A.L. consults for Collaborative Drug Discovery Inc.

Acknowledgments

SE acknowledges several discussions with Dr. Megan Coffee, Dr. Joel S. Freundlich, Dr. Nancy Connell and Dr. Peter Madrid.

Grant information

The author(s) declared that no grants were involved in supporting this work.

Supplementary material

Supplemental Table 1. 55 compounds identified from the literature as *in vitro* or *in vivo* active against the Ebola virus. Molecule structures in various 2D formats are provided along with simple molecular descriptors, information relating to the target if known, indication, publication reference as well as medicinal chemistry insights and PAINS filter failures.

<http://dx.doi.org/10.5256/f1000research.6120.s42952>

References

- Martinez JP, Sasse F, Brønstrup M, *et al.*: **Antiviral drug discovery: broad-spectrum drugs from nature.** *Nat Prod Rep.* 2015; **32**(1): 29–48.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Anon. **World Health Organization media center.** 2014.
[Reference Source](#)
- Debing YD, Jochmans J, Neyts J: **Intervention strategies for emerging viruses: use of antivirals.** *Curr Opin Virol.* 2013; **3**(2): 217–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Simmons CP, Wolbers M, Nguyen MN, *et al.*: **Therapeutics for dengue: recommendations for design and conduct of early-phase clinical trials.** *PLoS Negl Trop Dis.* 2012; **6**(9): e1752.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Stadler K, Massignani V, Eickmann M, *et al.*: **SARS—beginning to understand a new virus.** *Nat Rev Microbiol.* 2003; **1**(3): 209–18.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Raj VS, Osterhaus AD, Fouchier RA, *et al.*: **MERS: emergence of a novel human coronavirus.** *Curr Opin Virol.* 2014; **5**: 58–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- De Clercq E: **Strategies in the design of antiviral drugs.** *Nat Rev Drug Discov.* 2002; **1**(1): 13–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
- De Clercq E: **Antivirals and antiviral strategies.** *Nat Rev Microbiol.* 2004; **2**(9): 704–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
- De Clercq E: **Ebola virus (EBV) infection: Therapeutic strategies.** *Biochem Pharmacol.* 2015; **93**(1): 1–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Brown CS, Lee MS, Leung DW, *et al.*: ***In silico* derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity.** *J Mol Biol.* 2014; **426**(10): 2045–58.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Han Z, Lu J, Liu Y, *et al.*: **Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses.** *J Virol.* 2014; **88**(13): 7294–306.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Opsenica I, Burnett JC, Gussio R, *et al.*: **A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, *P. falciparum* malaria, and the Ebola filovirus.** *J Med Chem.* 2011; **54**(5): 1157–69.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Johnson JC, Martinez O, Honko AN, *et al.*: **Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells.** *Antiviral Res.* 2014; **107**: 102–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Johansen LM, Brannan JM, Delos SE, *et al.*: **FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.** *Sci Transl Med.* 2013; **5**(190): 190ra79.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Madrid PB, Chopra S, Manger ID, *et al.*: **A systematic screen of FDA-approved drugs for inhibitors of biological threat agents.** *PLoS One.* 2013; **8**(4): e60579.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

16. Gehring G, Rohrmann K, Atenchong N, *et al.*: **The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry.** *J Antimicrob Chemother.* 2014; **69**(8): 2123–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Ekins S, Freundlich JS, Coffee M: **A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus.** [v1; ref status: indexed, <http://f1000res/4qh>]. *F1000Res.* 2014; **3**(277).
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Kazmi, F, Hensley T, Pope C, *et al.*: **Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).** *Drug Metab Dispos.* 2013; **41**(4): 897–905.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Nadanaciva S, Lu S, Gebhard DF, *et al.*: **A high content screening assay for identifying lysosomotropic compounds.** *Toxicol In Vitro.* 2011; **25**(3): 715–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Oestereich L, Lüdtke A, Wurr S, *et al.*: **Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model.** *Antiviral Res.* 2014; **105**: 17–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Anon. **French nurse cured of Ebola contracted in Liberia.** 2014.
[Reference Source](#)
22. Florescu DF, Keck MA: **Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses.** *Expert Rev Anti Infect Ther.* 2014; **12**(10): 1171–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Anon. **Chimerix's Brincidofovir Has in Vitro Activity Against Ebola.** 2014.
[Reference Source](#)
24. Bishop BM: **Potential and Emerging Treatment Options for Ebola Virus Disease.** *Ann Pharmacother.* 2015; **49**(2): 196–206.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Warren TK, Wells J, Panchal RG, *et al.*: **Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430.** *Nature.* 2014; **508**(7496): 402–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Litterman N, Lipinski CA, Bunin BA, *et al.*: **Computational Prediction and Validation of an Expert's Evaluation of Chemical Probes.** *J Chem Inf Model.* 2014; **54**(10): 2996–3004.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Lipinski CA, Litterman NK, Southan C, *et al.*: **Parallel Worlds of Public or Commercial Bioactive Chemistry Data.** *J Med Chem.* 2014; In Press.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Baell JB, Holloway GA: **New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays.** *J Med Chem.* 2010; **53**(7): 2719–2740.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Baell J, Walters MA: **Chemistry: Chemical con artists foil drug discovery.** *Nature.* 2014; **513**(7519): 481–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Clark AM, Williams AJ, Ekins S: **Cheminformatics workflows using mobile apps.** *Chem-Bio Informatics J.* 2013; **13**: 1–18.
[Reference Source](#)
31. Wolf MC, Freiberg AN, Zhang T, *et al.*: **A broad-spectrum antiviral targeting entry of enveloped viruses.** *Proc Natl Acad Sci U S A.* 2010; **107**(7): 3157–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Hohman M, Gregory K, Chibale K, *et al.*: **Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery.** *Drug Discov Today.* 2009; **14**(5–6): 261–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Ekins S, Freundlich JS, Hobarth JV, *et al.*: **Combining computational methods for hit to lead optimization in *Mycobacterium tuberculosis* drug discovery.** *Pharm Res.* 2014; **31**(2): 414–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Ekins S, Reynolds RC, Kim H, *et al.*: **Bayesian Models Leveraging Bioactivity and Cytotoxicity Information for Drug Discovery.** *Chem Biol.* 2013; **20**(3): 370–378.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Veljkovic V, Loiseau PM, Figadere B, *et al.*: **Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection.** *F1000Res.* 2015; **4**: 34.
[Publisher Full Text](#)
36. Kouznetsova J, Sun W, Martínez-Romero C, *et al.*: **Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs.** *Emerging Microbes Infect.* 2014; **3**: e84.
[Publisher Full Text](#)
37. Long J, Wright E, Molesti E, *et al.*: **Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry.** *F1000Res.* 2015; **4**: 30.
[Reference Source](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 19 February 2015

<https://doi.org/10.5256/f1000research.6555.r7713>

© 2015 Anderson P. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Paul S Anderson

Independent Pharmaceuticals Professional, Lansdale, PA, 19446, USA

The authors have collected 55 small molecules reported to have activity against the ebola virus from the literature and organized them into a dataset that is easily searchable for those who may be interested in pursuing further research on the design of inhibitors of this virus.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 02 Mar 2015

Sean Ekins, Collaborative Drug Discovery, 1633 Bayshore Highway, Suite 342, Burlingame, USA

Thank you for your positive review comments.

Competing Interests: None

Reviewer Report 11 February 2015

<https://doi.org/10.5256/f1000research.6555.r7611>

© 2015 Lowe III J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

John A. Lowe III

JL3Pharma LLC, Stonington, CT, USA

The authors have searched a collection of compounds for a common pharmacophore directed against Ebola proteins, and detected 55 hits. These were filtered by an experienced medicinal chemist using well-established techniques and intuition to provide 16 legitimate compounds that may serve the Ebola research community as a publicly available resource. This is an excellent example of the power of shared, collaborative research databases providing valuable resources to the research community.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 02 Mar 2015

Sean Ekins, Collaborative Drug Discovery, 1633 Bayshore Highway, Suite 342, Burlingame, USA

Thank you for your review and comments!

Competing Interests: None

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research